Table 3 A list of mass spectrometry-based urinary peptidomics studies in cancer and other diseases since 2011

Normal human urine peptidomics

Numerous separation and extraction method developed for efficient enrichment of endogenous urinary peptides in healthy individuals. Along with profiling, age-related urinary peptidomics has been carried out in individuals with different age groups. These studies provide substantial foundation for disease-related peptide identification in urine

CE-TOF–MS

nanoLC-TOF–MS

MALDI-TOF–MS

LC–MS/MS

Q-TOF LC–MS

[138]

[294]

[139]

[145]

[146]

[142]

[144]

[41]

[143]

[295]

[296]

Urine peptidomics in cancer

Differential urinary peptidomic analysis for several cancer types including bladder cancer, ovarian cancer, prostate cancer and renal cell carcinoma (RCC) has been performed for detecting non-invasive peptide biomarkers in urine for clinical manifestation and disease management

MALDI-TO-MS

LC–MS/MS

CE-MS

PRM-MS

[297]

[298]

[299]

[150]

[151]

[300]

[153]

[134]

Urine peptidomics in other diseases

Non-invasive biosignature identification in diverse conditions including chronic kidney diseases (CKD), in infection, celiac disease, diabetes, hypertension, neurological disorders, in kidney transplant and drug monitoring, COVID-19, preeclampsia and cardiovascular disorders using mass spectrometry-based urine peptidomics in both discovery and targeted fashion

MALDI-TOF/TOF

MRM-MS

LC–MS/MS

CE-MS

Q-TOF LC–MS

[301]

[42]

[302]

[156]

[303]

[304]

[137]

[305]

[306]

[307]

[308]

[154]

[159]

[309]

[158]

[310]

[311]

[312]

[313]

[160]

[157]

[314]

[136]

[161]

[315]

[316]

[162]

[317]

[318]